Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

Jansen, Jeroen P; Buckley, Felicity; Dejonckheere, Fred; Ogale, Sarika

doi:10.1186/1477-7525-12-102

Table 1 Study and patient baseline characteristics of studies included in the network meta-analysis

From: Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

Study	Interventions	Number of patients	AGE (years)	Female (%)	Disease duration (years)	SJC (0–66)	TJC (0–68)	ESR (mm/hr)	CRP (mg/L)	RF + ve number (%)
Kremer [44]	ABT 10 mg/kg Q4W + MTX	115	56	75	10	21.3	30.8	NR	29	90
Kremer [44]	Placebo + MTX	119	55	66	9	21.8	29.2	NR	32	90
Kremer [43], Russell [47]	ABT 10 mg/kg Q4W + MTX	433	52	78	9	21.4	31	NR	33	82
Kremer [43], Russell [47]	Placebo + MTX	219	50	82	9	22.1	32.3	NR	28	79
Cohen [36]	ANA 100 mg QD + MTX	250	56	79	11	20.1	26.8	41.5	27	76
Cohen [36]	Placebo + MTX	251	57	75	10	20	24.5	42.9	26	78
Maini [46], Lipsky [45] (ATTRACT)	IFX 3 mg/kg Q8W + MTX	86	54	81	10	22	32	49	39	84
Maini [46], Lipsky [45] (ATTRACT)	Placebo + MTX	88	51	80	11	21	31	49	40	77
Keystone [41], Yount [56]	ADA 40 mg QOW + MTX	207	56	76	11	19.3	27.3	NR	18	82
Keystone [41], Yount [56]	Placebo + MTX	200	56	73	11	19	28.1	NR	18	90
Weinblatt [54], Yount [56] (ARMADA)	ADA 40 mg QOW + MTX	67	57	75	12	17.3	28	NR	21	NR
Weinblatt [54], Yount [56] (ARMADA)	Placebo + MTX	62	56	82	11	16.9	28.7	NR	31	NR
Van de Putte [11]	ADA 40 mg QOW	113	53	80	11	20.5	33.7	55.8	52.6	80
Van de Putte [11]	Placebo	110	54	77	12	19.8	35.5	56.1	57	82
Strand [51], (RAPID 1)	CTZ 200 mg QOW + MTX	393	51	82	6	9.9 ^M	12.4 ^M	43.5 ^M	16 ^M	80
Strand [51], (RAPID 1)	Placebo + MTX	199	52	84	6	9.7 ^M	13 ^M	45 ^M	16 ^M	83
Smolen [50], Strand [52], (RAPID 2)	CTZ 200 mg QOW + MTX	246	52	84	6	20.5	30.1	43.7	14.2	78
Smolen [50], Strand [52], (RAPID 2)	Placebo + MTX	127	52	84	6	21.9	30.4	40.8	13.5	78
Fleischmann [39] (FAST4WARD)	CTZ 400 mg Q4W	111	53	78	9	21.2	29.6	30.9	11.6	100
Fleischmann [39] (FAST4WARD)	Placebo	109	55	89	10	19.9	28.3	35.6	11.3	100
Weinblatt [55]	ETN 25 mg BW + MTX	59	48	90	13	20	28	25	22	84
Weinblatt [55]	Placebo + MTX	30	53	73	13	17	28	36	26	90
Moreland [10], Mathias [9]	ETN 25 mg BW	78	53	74	11	25	33	35	47	79
Moreland [10], Mathias [9]	Placebo	80	51	76	12	25	35	39	41	79
Keystone [42] (GO-FORWARD)	GLB 50 mg Q4W + MTX	89	52 ^M	81	4.5 ^M	13 ^M	26 ^M	NR	10 ^M	81
Keystone [42] (GO-FORWARD)	Placebo + MTX	133	52 ^M	82	6.5 ^M	12 ^M	21 ^M	NR	8 ^M	81
Genovese [40] (TOWARD)	TCZ 8 mg/kg Q4W + MTX	803	53	81	10	19.7	30.1	48.2	26	NR
Genovese [40] (TOWARD)	Placebo + MTX	413	54	84	10	18.7	29.1	49.2	26	NR
Smolen [49] (OPTION)	TCZ 8 mg/kg Q4W + MTX	205	51	NR	8	19.5	31.9	51.2	26	83
Smolen [49] (OPTION)	Placebo + MTX	204	51	NR	8	20.7	32.8	49.7	24	71
ACT-RAY	TCZ 8 mg/kg Q4W + MTX	277	53	81.9	8.2	14.4	25.8	39.9	NR	NR
ACT-RAY	TCZ 8 mg/kg Q4W	276	53.6	78.6	8.3	15.3	26.6	39.6	NR	NR
ADACTA	TCZ 8 mg/kg	163	54.4	79	7.3	11.3	15.9	50.5	26	NR
ADACTA	ADA 40 mg	162	53.3	82	6.3	12.4	16.5	45.5	25	NR

M = median; NR = not reported; SJC = swollen joint count; TJC = tender joint count; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; RF + ve = Rheumatoid factor positive ABT = abatacept; ANA = anakinra; IFX = infliximab; ADA = adalimumab; CTZ = certolizumab pegol; ETN = etanercept; GLB = golimumab; TCZ = tocilizumab; MTX = methotrexate.

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us